• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Baird Medical Investment Holdings Ltd

    1/28/25 6:02:03 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care
    Get the next $BDMD alert in real time by email
    6-K 1 tm254530d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of January 2025

    Commission File Number 001-42300

     

    Baird Medical Investment Holdings Limited

     

    Room 202, 2/F, Baide Building, Building 11, No.15
    Rongtong Street, Yuexiu District, Guangzhou,

    Peoples Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F   x  Form 40-F   ¨  

     

     

     

     

     

     

    Change of Auditor

     

    On January 24, 2025, Baird Medical Investment Holdings Limited (the “Company”), upon the approval and ratification of the board of directors of the Company (the “Board”) and the audit committee of the Board (the “Audit Committee”), dismissed Marcum Asia CPAs LLP (“Marcum Asia”), the former independent registered public accounting firm of the Company, effective on January 24, 2025, and appointed Kreit & Chiu CPA LLP (PCAOB ID: 6651) (the “New Auditor”) to serve as its independent registered public accounting firm, effective on January 24, 2025, for the year ended December 31, 2024.

     

    Marcum Asia’s reports on the Company’s financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimers of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

     

    Furthermore, during the fiscal years ended December 31, 2023 and 2022 and through January 24, 2025, there were no disagreements, as defined in Item 16F(a)(1)(iv) of Form 20-F, with Marcum Asia on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum Asia, would have caused Marcum Asia to make reference to the subject matter of the disagreements in connection with its reports on the Company’s financial statements for such year. In addition, during this time, there were no “reportable events,” as defined in as defined in Item 16F(a)(1)(v)(A)-(D) of Form 20-F, except for the material weaknesses related to the Company’s internal control over financial reporting, including (i) lack of sufficient financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting requirements to properly address certain accounting issues and to prepare and review financial statements and related disclosures in accordance with U.S. GAAP and SEC reporting requirements; and (ii) lack of comprehensive accounting policies and procedures manual in accordance with U.S. GAAP and documented controls which enable management and other personnel to understand and carry out their internal control responsibilities.

     

    The Company provided Marcum Asia with a copy of the above disclosure and requested that Marcum Asia furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether or not it agrees with the above statements. A copy of Marcum Asia’s letter is filed as Exhibit 16.1 to this Form 6-K.

     

    During the two most recent fiscal years and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted the New Auditor regarding any of the matters described in Item 16F(a)(2)(i) and (ii) of Form 20-F. The New Auditor is aware of the material weaknesses described above and understands it is a reportable event.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Dated: January 28, 2025
         
      By: /s/ Haimei Wu
      Name: Haimei Wu
      Title: Chairwoman and Chief Executive Officer

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit 
    Number
      Description
    16.1   Letter of Marcum Asia CPAs LLP to the U.S. Securities and Exchange Commission dated January 28, 2025

     

     

     

    Get the next $BDMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BDMD
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Baird Medical Investment Holdings Ltd

    F-1/A - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    8/8/25 4:04:26 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by Baird Medical Investment Holdings Ltd

    20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    5/15/25 4:17:12 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    SEC Form NT 20-F filed by Baird Medical Investment Holdings Ltd

    NT 20-F - Baird Medical Investment Holdings Ltd (0001982444) (Filer)

    4/30/25 4:56:28 PM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baird Medical Announces First Successful Liver Tumor Ablation in Bangladesh

    NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful completion of its first MWA procedure in Bangladesh. The landmark treatment was performed at USB Hospital in Uttara, Dhaka, marking a significant step forward in the availability of cutting-edge, non-surgical cancer therapies in the region. The procedure was led by Dr. Mofazzal Sharif Rasel, a distinguished interventional radiologist, and his expert medical team. The patient, a 65

    10/23/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    /C O R R E C T I O N -- BDMD/

    In the news release, Baird Medical Fosters Advanced Physician Training at International Thyroid Microwave Ablation Workshop in Malaysia, issued 21-Oct-2025 by BDMD over PR Newswire, we are advised by the company that the second paragraph, second sentence, should read "Led by a distinguished faculty, Proctor Dr. Shuhang Xu, endocrinologist at Jiangsu Provincial Hospital, alongside HCTM's B&E Surgeons Dr. Adi Syazni and Prof. Shahrun Niza, the program featured a rigorous curriculum encompassing theoretical lectures, complex case discussions, and practical training sessions using both mannequins and live patient cases." rather than "...endocrinologist at Nanjing University of Traditional Chines

    10/21/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    Baird Medical Fosters Advanced Physician Training at International Thyroid Microwave Ablation Workshop in Malaysia

    NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its successful participation in the Thyroid Microwave Ablation Workshop held at the Hospital Canselor Tuanku Muhriz (HCTM) of The National University of Malaysia. The immersive two-day workshop, held from October 1–2, 2025, brought together leading surgeons and endocrinologists for intensive, hands-on training. Led by a distinguished faculty, Proctor Dr. Shuhang Xu, endocrinologist at Nanjing Un

    10/21/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care

    $BDMD
    Leadership Updates

    Live Leadership Updates

    View All

    Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

    NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025. Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share

    10/20/25 8:30:00 AM ET
    $BDMD
    Medical/Dental Instruments
    Health Care